

Another financing round by a Xenia portfolio company:

Medi-tate Raises Approximately \$2 Million

Medi-tate has an innovative minimally-invasive product for treating benign prostate hyperplasia, which affects 20-50% of men over 65

Tel Aviv, 5 May 2015 – Xenia Venture Capital Ltd. (TASE: XENA), an Israeli investment company that specializes in the development of technology-intensive start ups, has announced a \$2 million financing round by portfolio company Medi-tate Ltd. (in which Xenia owns a 22.25% stake, fully diluted). Medi-tate develops products for treating diseases of the urethra and prostate. The flagship product of Medi-tate, iTIND 555, is designed to treat patients suffering from benign prostate hyperplasia (BPH). The company has obtained CE marking for marketing the device in Europe.

According to Xenia CEO, Anat Segal: "We are very pleased with the closing of an important financing round in Medi-tate. The company's products, which show good results in clinical trials, target a \$1 billion market in Europe alone. Medi-tate's product treats benign prostate hyperplasia with an innovative medical device through a minimally invasive procedure that takes just a few minutes. In addition to having a proven clinical advantage, the product is simple and easy to use by doctors and is preferable to current treatments, whether with medications or aggressive and expensive surgical procedures.

Medi-tate joins a group of portfolio companies which continues to show business achievements. We are moving our companies forward and believe that we will announce follow-on financing rounds and meet significant milestones during 2015, creating value for our shareholders."

In addition to a potential \$1 billion market in Europe, 15 million men suffer from benign prostate hyperplasia in the US, of whom only around three million receive treatment, 90% with medications and 10% through surgical procedures. In the United States this market is estimated while in the rest of the world more than 500,000 procedures are carried out every year.

About Xenia Venture Capital

Xenia Venture Capital is a hi-tech investment company publicly traded in the Tel Aviv Stock Exchange (TASE). Xenia is engaged in investing in early stage companies in the areas of high tech and med tech in Israel. Xenia also holds 50% of **VLX**, a technological incubator operating under the incubator program of the Office of the Chief Scientist of the State of Israel (**OCS**).

In addition to financing, **Xenia** provides its companies with top-notch mentoring, business and strategic counseling, fund raising assistance and exit planning, as well as basic infrastructure and peripheral services (finance & accounting, logistics, office support, etc).

Xenia's portfolio companies include the following:

Superfish – a visual web-based search engine with over 80 million users.

Polypid – a platform for local, delayed and controlled release of a range of drugs in a wide variety of applications, including orthopedics and dental implants.

Playcast – a technological platform for cloud-based games.

Saguna – a software offering mobile caching to relieve loads in mobile networks due to the increasing volumes of video and image content in these networks.

OrthoSpace– which developed a degradable balloon implant for treating the rotator cuff syndrome.